XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Agreements and Contracts - Acquisition of ACEA Therapeutics, Inc. - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
9 Months Ended
Jun. 30, 2022
Jun. 01, 2021
Sep. 30, 2022
Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Goodwill     $ 80,199 $ 79,525
Acquired in-process research and development        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Impairment charges $ 90,800      
ACEA Therapeutics, Inc        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Business acquisition, effective date of acquisition     Jun. 01, 2021  
Business acquisition, name of acquired entity     ACEA  
Stock consideration shares value   $ 38,100    
Stock consideration value   5.5    
Stock consideration value per share (usd per share)   $ 6.8955    
Business combination additional payments   $ 450,000    
Business combination current liability true up amount     $ 7,500  
Upfront consideration   44,100    
Impairment charges   90,800    
Goodwill   36,000    
Fair value of debt assumed liability   32,100    
Deferred tax liabilities assumed   31,400    
Purchase price allocation resulted in net identifiable assets, other net assets   2,900    
ACEA Therapeutics, Inc | Acquired in-process research and development        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Purchase price allocation resulted in net identifiable assets   $ 190,800    
ACEA Therapeutics, Inc | Minimum        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Percentage of annual net sales on royalty bearing products   5.00%    
ACEA Therapeutics, Inc | Maximum        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Percentage of annual net sales on royalty bearing products   10.00%